secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193805-26-000573
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q1 net loss widens to $27M; appoints Dennis Mulroy as CFO
------------------------------------------------------------------

- Net loss of $27.0M ($0.95/diluted share), compared to $14.1M loss ($0.52/share) in Q1 2025.
- Total operating expenses fell to $31.0M from $46.2M; revenue down $27.3M due to pivot from infectious disease.
- Cash and equivalents $213.4M, runway beyond Q2 2028. Cash decreased $19.4M from Dec 2025.
- ARCT-032 CF Phase 2 study enrollment initiated; ARCT-810 OTC deficiency gets FDA clarity for pivotal pediatric path.
- Dennis Mulroy appointed CFO effective May 1, 2026; base salary $520k, options for 100k shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/0001193805-26-000573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/e665435_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer